MedTrace Logo

L-Theanine in the Management of Schizophrenia

NCT00372151 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-12-16

No results posted yet for this study

Summary

The aim of the proposed study is to investigate the efficacy and safety of add-on gamma-glutamylethylamide (L-theanine) versus a placebo for antipsychotic treatment for 8 weeks in a randomized, double-blind, parallel group study of 60 patients with schizophrenia and schizoaffective disorders.

Conditions

Interventions

DIETARY_SUPPLEMENT

L-Theanine

400 mg/day, caps.

OTHER

Placebo

caps.

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Beersheva Mental Health Center

    collaborator OTHER_GOV

  • Sha'ar Menashe Mental Health Center

    lead OTHER

Principal Investigators

  • Michael S Ritsner, MD, PhD · Sha'ar Menashe Mental Health Center

  • Yael Ratner, MD · Sha'ar Menashe Mental Health Center

  • Anatoly Gibel, MD · Sha'ar Menashe Mental Health Center

  • Chanoch Miodownik, MD · Be'er Sheva Mental Health Center

  • Tatyana Shleifer, MD · Be'er Sheva Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00372151 on ClinicalTrials.gov